focus -WSS

focus

author：leisure time 2025-09-27 09:40:02 - browse：4532

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.

For more on what we cover, here’s all of Rachel’s coverage; here’s more on Vertex’s competition; here’s the news on Gilead; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

explore

focus

WSS

Intellia reports positive results for its CRISPR

BMI, flaws aside, is found to be useful estimate of body fat in youth

HIV drugs protect against transmission, even in unprotected sex

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Biden will tout long

entertainment

focus

focus

Bright Health sells Medicare Advantage business to Molina

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Intellia reports positive results for its CRISPR

Wildfire smoke exposes gaps in outdoor worker protections

Illinois to ban advertising for guns allegedly marketed to kids and militants

The high cost of giving birth even with insurance

Intellia reports positive results for its CRISPR

Medical records are filled with copy

Cord blood banking comes at a high cost to babies

focus

Illinois to ban advertising for guns allegedly marketed to kids and militants

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Ultragenyx gene therapy for rare liver ailment succeeds in late

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

knowledge

explore

focus

leisure time